Severe Asthma Clinical Trial Pipeline Appears Robust With 40+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight [Yahoo! Finance]
Kymera Therapeutics, Inc. (KYMR)
Company Research
Source: Yahoo! Finance
therapies like biologics targeting IgE and cytokine modulators. A growing demand for personalized medicine enhances treatment efficacy and patient compliance. Government initiatives and increased awareness improve access to care, while advancements in inhaler technology boost medication adherence. Collaborative efforts in R&D are also vital for driving innovation in asthma treatments. LAS VEGAS Nov. 6, 2024 /PRNewswire/ -- DelveInsight's Severe Asthma Pipeline Insight 2024 report provides comprehensive global coverage of pipeline severe asthma therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the severe asthma pipeline domain. Key Takeaways from the Severe Asthma Pipeline Report DelveInsight's severe asthma pipeline report depicts a robust space with active players working to develop pipeline therapies for severe asthma treatment. Key severe asthma companies such as Kinas
Show less
Read more
Impact Snapshot
Event Time:
KYMR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KYMR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KYMR alerts
High impacting Kymera Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
KYMR
News
- Kymera Therapeutics, Inc. (NASDAQ: KYMR) had its price target raised by analysts at Morgan Stanley from $45.00 to $49.00. They now have an "equal weight" rating on the stock.MarketBeat
- Kymera Therapeutics to Participate in Upcoming November Investor ConferencesGlobeNewswire
- Kymera Therapeutics, Inc. (NASDAQ: KYMR) had its price target lowered by analysts at UBS Group AG from $80.00 to $74.00. They now have a "buy" rating on the stock.MarketBeat
- Analysts Have Made A Financial Statement On Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Third-Quarter Report [Yahoo! Finance]Yahoo! Finance
- Kymera Therapeutics, Inc. (NASDAQ: KYMR) had its price target raised by analysts at Guggenheim from $45.00 to $52.00. They now have a "buy" rating on the stock.MarketBeat
KYMR
Earnings
- 10/31/24 - Beat
KYMR
Sec Filings
- 11/12/24 - Form SC
- 11/8/24 - Form SC
- 10/31/24 - Form S-3ASR
- KYMR's page on the SEC website